a 180 000 molecular weight protein composed of disulphide linked 75 kilodalton subunits. Like fibronectin, chondronectin circulates in plasma, though at concentrations approximately one tenth of circulating fibronectin (-10 mg/I).
Several matrix proteins have been detected in the synovial fluid of patients with rheumatic disease. It has been suggested that the presence of matrix proteins and their degradation products may be sensitive indicators of matrix breakdown and repair in arthritis. Synovial fluid fibronectin concentrations are higher than plasma fibronectin levels in rheumatoid arthritis (RA), correlate with synovial fluid white blood cell counts, and appear to be an indicator of proliferative disease.2 Collagen I and III peptides have also been detected in inflammatory synovial fluid. The quantity of collagen peptide recovered in synovial fluid pellets has been shown to correlate with the degree of joint destruction radiographically. 3 Although chondronectin has been localised to cartilage matrix, it is not known if it is present in the plasma. Plasma chondronectin has not been systematically studied in patients with arthritis, but preliminary data suggest that chondronectin concentrations in the plasma of patients with arthritis are similar or slightly higher than normal plasma concentrations. The measurement of chondronectin in synovial fluid by competitive ELISA did not appear to be influenced by synovial fluid as dilutionbinding curves were parallel and nearly identical whether performed in the presence of synovial fluid or plasma. Synovial fluid concentrations also appeared not to reflect the presence of chondronectin proteolytic degradation products in the inflamed joint as immunoblotting studies showed the presence of an intact 75 kilodalton subunit in synovial fluid as well as plasma. In addition, lower molecular weight bands corresponding to potential proteolytic fragments were not seen. Although chondronectin concentrations in RA fluids were slightly higher than those in OA fluids, these differences were not statistically significant. The ratio of chondronectin to fibronectin was approximately 1 7-fold higher in OA fluid than in RA fluid. This may primarily represent differences in fibronectin concentrations. Alterations in relative quantities of matrix proteins in synovial fluid may influence the phenotypic behaviour of synovial cells. Further studies will be necessary to determine the use of matrix protein measurement in the clinical and pathological evaluation of joint destruction.
When the subgroup of RA fluids was analysed the synovial fluid chondronectin concentrations were found to correlate positively with concentrations of synovial fluid fibrinogen and albumin. Synovial fluid chondronectin correlated less strongly with concentrations of fibronectin, which appears to be locally synthesised. Albumin and fibrinogen are not locally synthesised and enter synovial fluid by diffusion from plasma in the presence of inflammation. Thus albumin and fibrinogen concentrations in synovial fluid never exceed those in plasma, though their concentration in synovial fluid appears to correlate with the degree of inflammation present. These data taken together with the data on plasma-synovial fluid pairs (Table 2) suggest that synovial fluid chondronectin is in part derived from plasma. Alternatively, chondronectin released from cartilage matrix may enter the synovial space in larger quantities but may deposit in an insoluble form, inaccessible to measurement in synovial fluid.
The function of chondronectin in synovial fluid is not known. In RA chondrocytes released from partially degraded RA cartilage matrix may contribute to the formation of pannus. 8 The presence of soluble chondronectin in synovial fluid may mediate the recruitment of chondrocytes to the synovial space, where under the influence of fibronectin they could undergo alteration to a phenotype characteristic of cells derived from pannus. 
